Roche Holding AGXSWX:ROP +2.09%79 EBITDA Margin % is 30.87% as of Dec. 2025, which is 8% below its 10-year median of 33.41. GuruFocus rates XSWX:ROP with a GF Score™ of 79/100 and a GF Value™ of CHF264.69 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 955 Drug Manufacturers companies, Roche Holding AG ranks better than 90.05% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Roche Holding AG's EBITDA for the
six
months ended in Dec. 2025 was CHF9,727 Mil. Roche Holding AG's Revenue for the
six
months ended in Dec. 2025 was CHF31,507 Mil. Therefore, Roche Holding AG's EBITDA margin for the quarter that ended in Dec. 2025 was 30.87%.
Roche Holding AG (XSWX:ROP) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Roche Holding AG EBITDA Margin % Related Terms
Roche Holding AG EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Roche Holding AG's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ROP vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Roche Holding AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roche Holding AG EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Roche Holding AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roche Holding AG (XSWX:ROP) has a EBITDA Margin % of 30.87% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Roche Holding AG and its competitors. This is near median its historical median of 33.41. Over the past decade, Roche Holding AG's EBITDA Margin % has ranged from 26.64 to 39.57. According to the industry distribution chart, Roche Holding AG ranks #95 out of 955 companies in the Drug Manufacturers industry, placing it in the top 9.9%.
Is Roche Holding AG's EBITDA Margin % too high?
Roche Holding AG's current EBITDA Margin % of 30.87% is near median its 10-year median of 33.41. Over the past 10 years, this metric has ranged from a low of 26.64 to a high of 39.57. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Roche Holding AG's value of 30.87% is 149.2% above this industry median. Based on the distribution chart, Roche Holding AG ranks #95 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Roche Holding AG has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Roche Holding AG ranks #95 out of 955 companies for EBITDA Margin %. This places Roche Holding AG in the top 10% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.39. Roche Holding AG's value of 30.87% is 149.2% above this benchmark. Historically, Roche Holding AG's own EBITDA Margin % has ranged from 26.64 to 39.57 over the past decade. While the company's 10-year median is 33.41 vs. the industry median of 12.39, Roche Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Roche Holding AG's current EBITDA Margin % of 30.87% is 149.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Roche Holding AG and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roche Holding AG's current EBITDA Margin % is 30.87%, which is near median its own 10-year median of 33.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:ROP) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF264.69, compared to a current price of CHF332.00 — trading 25.4% above its estimated fair value. The current EBITDA Margin % is 30.87%, which is near median its 10-year median of 33.41 and 149.2% above the Drug Manufacturers industry median of 12.39. Roche Holding AG's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Roche Holding AG (XSWX:ROP), the current EBITDA Margin % is 30.87% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roche Holding AG (XSWX:ROP) Overvalued in 2026?
Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued.
The current stock price of CHF332.00 is trading 25.4% above its estimated GF Value™ of CHF264.69.
GuruFocus considers Roche Holding AG to be Modestly Overvalued.
Key valuation signals for XSWX:ROP:
EBITDA Margin %: 30.87% (near median its 10-year median of 33.41)
GF Value™: CHF264.69 vs. price of CHF332.00 (25.4% above fair value)
Industry Position: 149.2% above the Drug Manufacturers median (#95 of 955)
No single metric tells the full story. See the XSWX:ROP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
79GF Score
Get the complete analysis for XSWX:ROP
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ROP has been successfully added to your 
